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Background: Single-center analyses have suggested that the number of CF pulmonary exacerbations (PEx) treated with intravenous antibiotics an
individual has experienced in the prior year is signiﬁcantly associated with their future PEx hazard.
Methods: We studied Prior-year PEx association with future PEx hazard by Cox proportional hazards regression among CF Foundation Patient
Registry patients who experienced PEx after Jan 1, 2010.
Results: Among 13,579 patients, those with 1, 2, 3, or ≥4 Prior-year PEx treated with intravenous antibiotics were at 1.8, 2.9, 4.8, and 8.7 higher
PEx hazard vs those without (P b .0001). Adjustment with signiﬁcant demographic and clinical covariates (univariate P ≤ .0001) reduced Prior-
year PEx hazard ratios to 1.6, 2.4, 3.6, and 6.0 (P b .0001). No other covariates had adjusted hazard ratios of N1.7.
Conclusions: Prior-year PEx strongly associate with future PEx hazard and should be accounted for in prospective trials where treatment-
associated change in PEx hazard is an efﬁcacy outcome.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Individuals with cystic fibrosis (CF) are susceptible to
pulmonary exacerbations (PEx), acute periods of intense increases
in signs and symptoms of lung infection coupled with decreased
lung function and other complications such as weight loss and/or
malaise [1]. Although a consensus prospective PEx definition
remains elusive, PEx-associated health outcomes have been
studied retrospectively using the surrogate marker of treatment
with antibiotics for respiratory symptoms [2–15]. Using this
approach, investigators have reported associations between CF
PEx treated with intravenous (IV) antibiotics and a variety ofthor at: 12520 33rd Street Ct E, Edgewood, WA 98372,
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ecommons.org/licenses/by-nc-nd/4.0/).adverse health outcomes, ranging from reduced quality of life to
an increased mortality risk [4,6,8–15]. Because of the recognized
clinical importance of IV-treated PEx, reduction in IV-treated PEx
hazard and increase in median time-to-next antibiotic treatment
for PEx have been used as efficacy endpoints in controlled trials of
both chronic CF respiratory therapies as well as PEx treatments
themselves [16,17].
Past IV-treatment of PEx has been identified as a significant
risk factor for future IV-treatment of PEx in individuals with
CF harboring multidrug-resistant bacterial airways infection
[2], as well as in more diverse CF populations [5,18]. In a
recent analysis of time-to-next IV-treated PEx among 193
pediatric and adult patients followed at the Cleveland Ohio
CF Care Center, we observed that the number of IV-treated PEx
an individual had experienced in the prior calendar year
(Prior-year PEx) had the strongest association with their futureCystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
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ment covariates analyzed [18]. Adjustment with covariates
previously reported to be associated with future PEx hazard had
little effect on the magnitude and or statistical significance of this
association. To test the hypothesis that this association exists for
the broader US CF population, we have characterized Prior-year
PEx number as an independent risk factor for future IV-treated
PEx among individuals followed in the US CF Foundation Patient
Registry (CFFPR) between 2009 and 2013 [19].
2. Methods
To be included in analyses, CFFPR patients had to have been
treated with IV antibiotics for PEx (termed a Care Episode in the
CFFPR) at least once on or after January 1, 2010, and to have had
at least one additional encounter or a death recorded after
completion of that Care Episode by December 31, 2013. Patients
also had to have data fields related to clinical complications
completed in the CFFPR case report form during the calendar
year (January through December) of their Index PEx, as well as
annualized data and at least one encounter recorded for each
calendar year included in the analyses (i.e., patients with an Index
PEx in 2010 and their next encounter recorded in 2012 were
excluded for lacking 2011 data). Care Episodes and clinic visits
occurring after lung transplantation were also excluded from
analyses. Adults and guardians of children followed in the
CFFPR provided consent for data analyses. CFFPR patient data
were de-identified prior to analyses, which were approved
prospectively by the CFFPR Registry Committee and the
University Hospitals Case Medical Center Institutional Review
Board (#01-15-15). Data management and manipulation were
performed in R version 3.1 (R Foundation for Statistical
Computing, Vienna, Austria). Statistical analyses were per-
formed with R v3.1 and MedCalc Statistical Software version
14.10.2 (MedCalc Software bvba, Ostend, Belgium).Prior-Year
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Fig. 1. Temporal relationships of care episodes, Index PEx, treatment duration, time
Episode for treatment of PEx recorded on or after Jan 1, 2010 during which at least o
of the Index PEx. Any subsequent PEx Care Episodes (CE2) that began shortly after t
start) were considered continuations of the same PEx and combined for analyses. Inde
CE1 to the end of all combined Care Episodes. PEx Care Episodes beginning ≥7 da
time to next PEx was calculated accordingly. For patients who had no subsequent PE
their last recorded clinic encounter was collected. Prior-year PEx were counted usin
method, where adjacent Care Episodes with gaps of b7 days were combined. In the e
the preceding year.The start date of a patient's first PEx Care Episode
beginning on or after January 1, 2010 was defined as the
beginning of their Index PEx. Methods for calculating Index
PEx treatment duration and time to next PEx are described
in Fig. 1. PEx beginning in the calendar year (January to
December) prior to the year of the Index PEx were counted for
each patient to create the covariate Prior-year PEx, combining
adjacent Care Episodes separated by b7 days (as in Fig. 1).
Demographic and treatment covariates for each patient were
collected from CFFPR Annual Review data for the calendar
year (January to December) in which their Index PEx began
and separately for the prior year. Categorical variables were
created from selected continuous variables (Prior-year PEx,
age at Index PEx end, body mass index [BMI], percent
predicted forced expiratory volume in 1 s [FEV1% predicted]),
where all missing values were assigned to a unique category.
Age and FEV1 categories were selected based on previous
analyses [12,18], BMI categories were chosen based on
distribution within the study population. For FEV1, missing
values were divided into separate categories for those patients
b6 years of age at the end of their Index PEx and those≥6 years
of age. The CFFPR uses the Global Lung Initiative normative
equations [20] to calculate FEV1% predicted. Duration of IV
treatment associated with the Index PEx was divided into three
categories: b9 days (‘short’), 9–14 days (‘usual’), and N14 days
(‘extended’).
Association of Prior-year PEx with time to next PEx was
studied by Kaplan–Meier survival analysis to select appropriate
categorical values of Prior-year PEx for subsequent analyses.
The potential for other demographic and clinical covariates
(e.g., age, FEV1, pulmonary complications) to account for
differences in time to next PEx associated with Prior-year PEx
was studied by Cox proportional hazard regression. Proportion-
ality of the Prior-year PEx covariate with respect to future
PEx hazard over time was investigated graphically by plottingIndex PEx
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to event, and Prior-year PEx. For each patient, the beginning of their first Care
ne day of IV antibiotics was administered (CE1) was identified as the beginning
he end of the previous episode (i.e., with a gap of b7 days from CE1 end to CE2
x PEx treatment duration was defined as the entire elapsed time from the start of
ys after the end of a previous PEx were considered the start of a next PEx, and
x Care Episodes, the elapsed time from the end of their Index PEx to the date of
g Care Episodes in the calendar year preceding the Index PEx using the same
xample shown, two Prior-year PEx consisted of three Care Episodes occurring in
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weighted residuals approach [21]. Cox proportional hazard
regression of Prior-year PEx for future PEx hazard was firstTable 1
Patient demographics during their index PEx year stratified by Prior-year PEx.
Prior-year PEx
None One Two
(N = 8098) (N = 2457) (N = 14
Age group, N (%) ⁎
b6 yrs 1123 (13.9%) 219 (8.9%) 85 (5.
6–12 yrs 1840 (22.7%) 460 (18.7%) 215 (14
13–17 yrs 1512 (18.7%) 464 (18.9%) 292 (19
18–24 yrs 1462 (18.1%) 580 (23.6%) 407 (27
25–50 yrs 1569 (19.4%) 565 (23.6%) 345 (23
N50 yrs 592 (7.3%) 169 (6.9%) 122 (8.
FEV1% predicted group, N (%) ⁎
≥100 1128 (13.9%) 198 (8.1%) 87 (6.
70 to b100 3339 (41.2%) 865 (35.2%) 471 (32
40 to b70 1910 (23.6%) 869 (35.4%) 554 (37
b40% 610 (7.5%) 299 (12.2%) 255 (17
NA, age b6 yrs 984 (12.2%) 191 (7.8%) 71 (4.
NA, age ≥6 yrs 127 (1.6%) 35 (1.4%) 28 (1.
BMI kg/m2
Mean (SD) 20.1 (4.2) 20.1 (4.0) 20.5 (4.
N (%) 8090 (99.9%) 2452 (99.8%) 1465 (99
F508del genotype, N (%) ⁎
Homozygous 4043 (49.9%) 1243 (50.6%) 724 (49
Heterozygous 2945 (36.4%) 900 (36.6%) 534 (36
No F508del 895 (11.1%) 227 (9.2%) 166 (11
Genotype NA 215 (2.7%) 87 (3.5%) 42 (2.
Female sex, N (%)
4001 (49.4%) 1314 (53.5%) 826 (56
Medicaid Insurance, N (%) ⁎
No 5195 (64.2%) 1428 (58.1%) 818 (55
Yes 2840 (35.1%) 1001 (40.7%) 627 (42
NA 63 (0.8%) 28 (1.1%) 21 (1.
Supplemental ventilation, N (%) ⁎
No 7786 (96.1%) 2325 (94.6%) 1377 (93
Yes 137 (1.7%) 72 (2.9%) 49 (3.
NA 175 (2.2%) 60 (2.4%) 40 (2.
Supplemental feeding, N (%) ⁎
No 3272 (40.4%) 956 (38.9%) 536 (36
Yes 4641 (57.3%) 1433 (58.3%) 892 (60
NA 185 (2.3%) 68 (2.8%) 38 (2.
Supplemental oxygen, N (%) ⁎
No 7076 (87.4%) 1998 (81.3%) 1066 (72
Yes 866 (10.7%) 407 (16.6%) 360 (24
NA 156 (1.9%) 52 (2.1%) 40 (2.
Smoker, N (%) ⁎
No 7482 (92.4%) 2224 (90.5%) 1290 (88
Yes 114 (1.4%) 54 (2.2%) 43 (2.
NA 502 (6.2%) 179 (7.3%) 133 (9.
Second-hand smoke exposure, N (%) ⁎
No 3879 (47.9%) 1094 (44.5%) 632 (43
Yes 1264 (15.6%) 447 (18.2%) 251 (17
NA 2955 (36.5%) 916 (37.3%) 583 (39
⁎ Column percentages; yrs = years; NA = covariate status not available.performed as univariate analysis and subsequently modeled
with inclusion of demographic and clinical complication
covariates with a univariate future PEx hazard ratio havingThree ≥Four All
66) (N = 762) (N = 796) (N = 13,579)
8%) 31 (4.1%) 30 (3.8%) 1488 (11.0%)
.7%) 106 (13.9%) 83 (10.4%) 2704 (19.9%)
.9%) 166 (21.8%) 171 (21.5%) 2605 (19.2%)
.8%) 223 (29.3%) 281 (35.3%) 2953 (21.7%)
.5%) 193 (25.3%) 196 (24.6%) 2868 (21.1%)
3%) 43 (5.6%) 35 (4.4%) 961 (7.1%)
0%) 25 (3.3%) 15 (1.9%) 1453 (10.7%)
.1%) 197 (25.9%) 155 (19.5%) 5027 (37.0%)
.8%) 351 (46.1%) 354 (44.5%) 4038 (29.7%)
.4%) 151 (19.8%) 227 (28.5%) 1542 (11.4%)
8%) 28 (3.7%) 25 (3.1%) 1299 (9.6%)
9%) 10 (1.3%) 20 (2.5%) 220 (1.6%)
0) 20.4 (3.7) 20.1 (3.8%) 20.1 (4.1)
.9%) 761 (99.9%) 794 (99.7%) 13,562 (99.9%)
.4%) 381 (50.0%) 401 (50.4%) 6792 (50.0%)
.4%) 281 (36.9%) 276 (34.7%) 4936 (36.4%)
.3%) 69 (9.1%) 77 (9.7%) 1434 (10.6%)
9%) 31 (4.1%) 42 (5.3%) 417 (3.1%)
.3%) 442 (58.0%) 464 (58.3%) 7047 (51.9%)
.8%) 386 (50.7%) 328 (41.2%) 8155 (60.1%)
.8%) 365 (47.9%) 445 (55.9%) 5278 (38.9%)
4%) 11 (1.4%) 23 (2.9%) 146 (1.1%)
.9%) 680 (89.2%) 666 (83.7%) 12,834 (94.5%)
3%) 57 (7.5%) 92 (11.6%) 407 (3%)
7%) 25 (3.3%) 38 (4.8%) 338 (2.5%)
.6%) 270 (35.4%) 205 (25.8%) 5239 (38.6%)
.8%) 475 (62.3%) 561 (70.5%) 8002 (58.9%)
6%) 17 (2.2%) 30 (3.8%) 338 (2.5%)
.7%) 483 (63.4%) 380 (47.7%) 11,003 (81.0%)
.6%) 254 (33.3%) 386 (48.5%) 2273 (16.7%)
7%) 25 (3.3%) 30 (3.8%) 303 (2.2%)
.0%) 663 (87.0%) 684 (85.9%) 12,343 (90.9%)
9%) 28 (3.7%) 28 (3.5%) 267 (2.0%)
1%) 71 (9.3%) 84 (10.6%) 969 (7.1%)
.1%) 320 (42.0%) 305 (38.3%) 6230 (45.9%)
.1%) 151 (19.8%) 164 (20.6%) 2277 (16.8%)
.8%) 291 (38.2%) 327 (41.1%) 5072 (37.4%)
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covariates among Prior-year PEx categories during the year of
the Index PEx were also tabulated. Proportional hazard
regressions were repeated using annualized clinical and
demographic covariates from the calendar year prior to the
Index PEx (i.e., the same year during which the covariate
Prior-year PEx was collected) as a sensitivity analysis.
In order to characterize associations of chronic pulmonary
medications prescribed during the Index PEx calendar year and
future PEx hazard, treatment covariates were tabulated by
Prior-year PEx category and characterized by univariate Cox
proportional hazard modeling and with adjustment for Prior-year
PEx. Patients missing all chronic pulmonary medication data
during their Index year were excluded from these analyses.
3. Results
Among 16,410 CFFPR patients experiencing an IV-treated
PEx on or after January 1, 2010, 13,579 met study inclusion
criteria and contributed an Index PEx to the analysis (Supple-
mental Fig. 5). Amajority of these patients (8098; 59.6%) had not
experienced a PEx treated with IV antibiotics in the prior calendar
year, while 18.1% (2457) had experienced one Prior-year
PEx, 10.8% (1466) had experienced two, and the remaining
11.5% (1558) had experienced three or more (Table 1).
A total of 10,694 patients (78.8%) experienced a second
Care Episode during which IV antibiotics were administered
for PEx after their Index PEx and prior to December 31, 2013.
Median time to next PEx from the end of the Index PEx
(accounting for censored patients) was 273 days [95% CI 267,
281]. The number of IV-treated PEx a patient had experienced
in the calendar year prior to their Index PEx (Prior-year PEx)
was strongly associated with time-to-next PEx by Kaplan–
Meier survival analysis. Median times to next PEx were
significantly different for patients with 0, 1, 2, 3, and 4
Prior-year PEx, while median times to next PEx for patients
with greater Prior-year PEx values were less well separated
(Fig. 2). Based on this observation, 796 patients with a
Prior-year PEx value ≥4 were combined into a single category0 50 100 150
0 Prior-Year PEx (N=8098)
1 Prior-Year PEx (N=2457)
2 Prior-Year PEx (N=1463)
3 Prior-Year PEx (N=762)
4 Prior-Year PEx (N=407)
5 Prior-Year PEx (N=186)
6 Prior-Year PEx (N=99)
7 Prior-Year PEx (N=41)
8 Prior-Year PEx (N=35)
9 Prior-Year PEx (N=11)
10 Prior-Year PEx (N=8)
11 Prior-Year PEx (N=4)
12 Prior-Year PEx (N=2)
4 Prior-Year Pex (N=796)
Median Tim
Fig. 2. Kaplan–Meier median time-to-PEx by number of Prior-year PEx. White bars
next PEx do not overlap with adjacent values. Gray bars show Prior-year PEx value
values. The black bar shows the median time to PEx for the group of pooled patienfor Prior-year PEx categorical analyses. Median time to next
PEx among patients with no Prior-year PEx was 389 days [379,
402], compared with 237 [226,250], 162 [155,170], 112 [105,
119], and 62 [56, 66] days among those with 1, 2, 3, and ≥4
Prior-year PEx (Figs. 2 and 3).
Some categorical demographic covariates showed consistent
increases in prevalence with increasing Prior-year PEx, including
female sex, Medicaid Insurance coverage, smoking, and
exposure to second hand smoke, as well as supplemental feeding,
ventilation, and oxygen utilization. In contrast, covariates such as
F508del genotype and mean BMI did not appear to differ
substantially across Prior-year PEx categories (Table 1). Among
individuals with an FEV1 recorded for the year of their Index
PEx, lower FEV1% predicted was associated with increased
Prior-year PEx, and patients 6 years of age or older with an
unknown FEV1 were more likely to have higher Prior-year PEx
values than those b6 years of age. Increasing age was associated
with higher Prior-year PEx values up to age 25, beyond which
there was a decrease in the proportion of patients with higher
Prior-year PEx values, suggestive of a survival effect.
The prevalence of clinical complications associated with CF,
including ABPA, massive hemoptysis, pneumothorax, sinus
disease, hepatic steatosis, GERD, CF-related diabetes, cirrhotic
and non-cirrhotic liver disease, pancreatitis, and hypertension
tended to increase as Prior-year PEx increased (Table 2).
Similarly, Pseudomonas aeruginosa, MRSA, and Burkholderia
cepacia complex isolation from respiratory secretions during
the Index PEx calendar year was more common in patients with
higher Prior-year PEx (Supplemental Table 3), as were the
prescription of most chronic pulmonary medications (Supple-
mental Table 4).
Proportionality of Prior-year PEx with respect to future
PEx hazard was observed to change with increasing observa-
tion time, being fairly consistent through the first 6 months
after the end of Index PEx treatment and becoming increas-
ingly less so with extended observation. For this reason, Cox
proportional hazard regressions were limited to the 24-week
period immediately following the end of Index PEx IV
treatment (gray box, Fig. 2).200 250 300 350 400 450
e to Next PEx with 95% CI (days)
highlight Prior-year PEx values where 95% CI for associated median times to
s where 95% CI for associated median times to next PEx overlap with adjacent
ts with Prior-year PEx ≥ 4. CI = confidence interval.
0 150 300 450 600 750 900 1050 1200 1350 1500
0
20
40
60
80
100
Time (days)
8098 6107 4259 2851 1952 1252 838 460 216 47 0
2457 1667 994 566 387 262 182 139 70 15 0
1466 791 332 163 113 78 53 40 17 2 0
762 266 89 41 21 13 10 8 3 1 0
796 126 46 20 13 8 6 3 1 0 0
Patients
without
Subsequent
PEx (%)
No Prior-Year PEx
One Prior-Year PEx
Two Prior-Year PEx
Three Prior-Year PEx
Four+ Prior-Year PEx
No Prior-Year PEx
One Prior-Year PEx
Two Prior-Year PEx
Three Prior-Year PEx
Four or More Prior-Year PEx
Fig. 3. Kaplan–Meier time-to-PEx by Prior-year PEx category. Vertical dashed lines represent censored patients. Patients at risk at different time points are shown for
each category below the plot. The 24 week period studied by Cox proportional hazards regression is highlighted with a gray box.
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categories over the 24 weeks following Index PEx treatment were
large and highly significant (P b .0001) by Cox proportional
hazards modeling, with hazard ratios among patients with
Prior-year PEx ranging from 1.8 to 8.7 compared with patients
who did not have an IV-treated PEx in the prior year (Fig. 4).
Adjustment of Prior-year PEx hazard ratios with demographic
and clinical covariates with significant (P ≤ .0001) univariate
associations with future PEx hazard modestly reduced observed
Prior-year PEx hazard ratios to a range of 1.6 to 6.0 (Fig. 4). ByTable 2
CF-related complications during the Index PEx year stratified by Prior-year PEx.
Prior-year PEx
None One
(N = 8098) (N =
Allergic bronchopulmonary aspergillosis (ABPA), N (%) 455 (5.6%) 19
Asthma, N (%) 2185 (27.0%) 73
Massive hemoptysis, N (%) 99 (1.2%) 4
Pneumothorax, N (%) 34 (0.4%) 1
Sinus disease, N (%) 2553 (31.5%) 82
Hepatic steatosis, N (%) 33 (0.4%)
Gastroesophageal reflux disease (GERD), N (%) 2386 (29.5%) 84
Glucose tolerance, N (%) ⁎
Normal 5838 (72.1%) 159
Impaired 736 (9.1%) 25
Diabetes 1461 (18.0%) 58
NA 63 (0.8%) 2
Liver disease, cirrhosis, N (%) 184 (2.3%) 7
Liver disease, non-cirrhosis, N (%) 426 (5.3%) 17
Liver disease, other, N (%) 192 (2.4%) 3
Pancreatitis, N (%) 121 (1.5%) 3
Hypertension, N (%) 176 (2.2%) 6
⁎ Column percentages; NA = covariate status not available.comparison, the largest adjusted future PEx hazard ratio among
all other covariates included in the model was 1.7 (oxygen
supplementation versus none, Fig. 4). Sensitivity analyses in
which Prior-year PEx hazard ratios were adjustedwith clinical and
demographic covariates collected during the calendar year prior to
the Index PEx had essentially no effect on this observation.
A total of 48 patients (0.4%) were missing all chronic
pulmonary medication data during their Index PEx year and
were excluded from modeling of associations between chronic
therapies and future PEx hazard ratios (Supplemental Table 4).Two Three ≥Four All
2457) (N = 1466) (N = 762) (N = 796) (N = 13,579)
0 (7.7%) 135 (9.2%) 76 (10.0%) 95 (11.9%) 951 (7.0%)
9 (30.1%) 499 (34.0%) 241 (31.6%) 251 (31.5%) 3915 (28.8%)
2 (1.7%) 37 (2.5%) 29 (3.8%) 33 (4.1%) 240 (1.8%)
5 (0.6%) 15 (1.0%) 7 (0.9%) 12 (1.5%) 83 (0.6%)
5 (33.6%) 548 (37.4%) 296 (38.8%) 294 (36.8%) 4516 (33.3%)
8 (0.3%) 5 (0.3%) 4 (0.5%) 7 (0.9%) 57 (0.4%)
8 (34.5%) 548 (37.4%) 319 (41.9%) 350 (44.0%) 4451 (32.8%)
6 (65.0%) 878 (59.9%) 410 (53.8%) 346 (43.5%) 9068 (66.8%)
1 (10.2%) 133 (9.1%) 94 (12.3%) 87 (10.9%) 1301 (9.6%)
2 (23.7%) 434 (29.6%) 247 (32.4%) 340 (42.7%) 3064 (22.6%)
8 (1.1%) 21 (1.4%) 11 (1.4%) 23 (2.9%) 146 (1.1%)
6 (3.1%) 50 (3.4%) 34 (4.5%) 46 (5.8%) 390 (2.9%)
2 (7.0%) 106 (7.2%) 66 (8.7%) 60 (7.5%) 830 (6.1%)
9 (1.6%) 24 (1.6%) 16 (2.1%) 14 (1.8%) 285 (2.1%)
9 (1.6%) 28 (1.9%) 16 (2.1%) 34 (4.3%) 238 (1.8%)
7 (2.7%) 51 (3.5%) 39 (5.1%) 41 (5.2%) 374 (2.8%)
0.6 1 3
PEx Hazard Ratio over 24 weeks with 95% CI
6 10
unadjusted
adjusted
ABPA vs None
6-12 Yrs vs <6 Yrs
13-17 Yrs vs <6 Yrs
18-24 Yrs vs <6 Yrs
25-50 Yrs vs <6 Yrs
>50 Yrs vs <6 Yrs
Asthma vs None
Impaired Glucose Tolerance vs None
CF-Related Diabetes vs None
Glucose Tolerance Unknown vs None
F508del Heterozygote  vs F508del Homozygote
No F508del vs F508del Homozygote
Genotype Unknown  vs F508del Homozygote
Female vs Male
FEV1 70-<100% Pred vs ≥100% Pred
FEV1 40-<70% Pred vs ≥100% Pred
FEV1 <40% Pred vs ≥100% Pred
FEV1 Unknown, age <6yrs vs ≥100% Pred
FEV1 Unknown, age ≥6yrs vs ≥100% Pred
GERD vs None
Massive Hemoptysis vs None
Hypertension vs None
Liver Disease, Cirrhosis vs None
Liver Disease, Non-Cirrhosis vs None
9-14 Days IV Treatment vs <9 Days
>14 Days IV Treatment vs <9 Days
Liver Disease, Other vs None
Oxygen Supplementation Unknown vs None
Oxygen Supplementation vs None
P. aeruginosa Isolation vs None
P. aeruginosa Unknown vs None
Pancreatitis vs None
None vs Any IV Treatment in Hospital
Pneumothorax vs None
One Prior-Year PEx vs No Prior-Year PEx
Two Prior-Year PEx vs No Prior-Year PEx
Three Prior-Year PEx vs No Prior-Year PEx
Four or More Prior-Year PEx vs No Prior-Year PEx
Second Hand Smoke Exposure vs None
Second Hand Smoke Exposure Unknown vs None
Sinus Disease vs None
Any Smoking vs None
Smoking Unknown vs None
Supplemental Ventilation vs None
Supplemental Ventilation Unknown vs None
Fig. 4. Unadjusted and adjusted Cox proportional hazards modeling of PEx hazard within 24 weeks of Index PEx treatment. Hazard ratios for demographic and
clinical complication covariates with univariate P ≤ .0001, as well as PEx treatment and P. aeruginosa isolation status covariates, are shown unadjusted (open
circles) and adjusted in a single Cox proportional hazards regression model (closed circles). Yrs = years, ABPA = allergic bronchopulmonary aspergillosis,
GERD = gastroesophageal reflux disease.
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ibuprofen, and inhaled corticosteroids) did not have a highly
significant (P b .0001) univariate association with increased
future PEx hazard within 6 months of the Index PEx; hazard
ratios for other therapies ranged from 1.18 for leukotrienemodifiers to 1.92 for inhaled colistimethate (Supplemental
Table 4). With the exception of hypertonic saline, addition of
Prior-year PEx to modeling as a categorical variable reduced
future PEx hazard associated with all other chronic therapies
over the 24 weeks following Index PEx treatment.
378 D.R. VanDevanter et al. / Journal of Cystic Fibrosis 15 (2016) 372–3794. Discussion
History of IV-treated PEx has been shown in previous
single-center analyses to be an important covariate associated
with future IV-treated PEx hazard among CF patients [2,18].
The current analysis of N13,500 CFFPR patients confirms and
expands upon these previous observations. The sample size of
our previous analysis of Cleveland CF Care Center patients
(N = 193) precluded distinction in future PEx hazard between
patients with one versus two IV-treated PEx in the prior year, or
for patients with three versus more than three PEx in the prior
year. With this much larger sample, we have observed that as
Prior-year PEx rises from zero through nine events, median
time to next PEx drops correspondingly (Fig. 3).
As with all observational registry studies, there are inherent
limitations to these analyses, as they are dependent on accurate
and complete capture of patient data by CF care centers, and we
were unable to randomly audit for data accuracy or submit
queries for missing data fields. In order to accurately assess
time to next PEx from the end of an Index PEx treatment, we
necessarily discarded N10% of patients who had apparently
useful Index PEx but who were lacking data between the
calendar year of their Index PEx and the calendar year of either
their next recorded PEx or censor date (Supplemental Fig. 5).
There is no method to determine whether the future PEx
hazards of these discarded patients were comparable with those
of retained patients. In addition, our analyses have been
necessarily limited to PEx treated with IV antibiotics, and it is
not possible to extrapolate our findings to risk of PEx treated
with antibiotics by other routes, which may not share this
relationship. Finally, the use of annualized data to adjust for
future PEx hazard is challenging, as clinical complications may
have arisen after both the Index PEx and subsequent PEx but
within the Index year. However, use of clinical complications
recorded in the prior year (which avoid this possible problem)
provided essentially identical results.
Interestingly, associations of PEx treatment decisions
(duration of IV treatment and location of treatment) with future
PEx risk that we had previously observed in our single center
analysis [18] were also observed in this more definitive study.
Very short IV treatments and those without hospital admission
were associated with increased hazard of future PEx, results
that run contrary to what might be expected from indication
bias (where ‘healthier’ patients might be expected to be treated
for shorter durations and/or without hospital admission and also
have reduced hazard) and warrant further attention.
That past behavior is predictive of future performance with
respect to PEx treatment with IV antibiotics is not a particularly
novel or unexpected finding [2,5,18], although it is not a covariate
that is uniformly included in Cox proportional hazard analyses
[22]. However, the remarkable strength of these relationships runs
counter to some aspects of current thinking regarding CF
exacerbation. PEx have been considered to be somewhat ‘random’
events (although it has been recognized that some patients are
more ‘prone’ to these events than others [2,3,5,18,22]) that can be
precipitated by stochastic ‘insults’ such as viral infection or air
pollution [1,23,24], as well as delayed or avoided by increasedintervention [1]. These are important assumptions when change in
PEx hazard is employed as an efficacy endpoint in randomized
interventional studies [16]. Our current results suggest that risk of
treatment with IV antibiotics among individuals with apparently
‘similar’ clinical and demographic profiles may differ by as much
as 6-fold within 6 months of their last PEx based solely on their
prior treatment history, although we cannot infer that this
covariate is also associated with risk of antibiotic treatment by
other routes. This observation has important ramifications for
design of randomized controlled CF trials that employ treatment-
associated change in IV-treated PEx hazard as an efficacy
endpoint: 1) stratification of subject randomization by Prior-year
PEx is more likely to balance baseline PEx hazard across
treatment groups than stratification by FEV1% predicted and/or
age, and 2) adjustment for Prior-year PEx when estimating
treatment-associated reductions in PEx hazard should reduce
variance and increase study power accordingly.
An individual's frequency of IV treatment for PEx in the
prior year is an ‘effect’ (as opposed to a cause) that has strong
association with future PEx hazard, but the underlying bases for
differences in PEx frequency and risk between apparently
similar patients remain uncharacterized. Differences may result
from (as yet uncaptured) biological differences between
patients, unique behavioral interactions between patients and
caregivers (note that this is a longitudinal phenomenon: in most
instances the same care team/patient pair will have participated
in past and future PEx treatments), or a mixture of both.
Regardless of the reason(s), an individual's propensity for IV
treatment of PEx in the near term (time periods commonly
covered by randomized clinical trials) appears to be less well
predicted by their age, lung function, sex, or the myriad of other
covariates followed in CF patient registries, as by their recent
treatment history. Further, although chronic pulmonary medi-
cations may attenuate future PEx hazard, these effects would
appear to be relatively modest compared with the magnitude of
hazard associated with PEx treatment history.
Supplementary data to this article can be found online at
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